Celsion
Corporation
’s
GEN-1 IL-12 Program
in Ad
vanced Ovarian Cancer
to be
Featured
in Poster Presentation
Chief Science Officer
Dr. Khursheed Anwer
to
Present and
Participate in
Two
Panel Discussions
LAWRENCEVILLE, N.J., Nov. 29, 2021 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN),
a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announces that Khursheed Anwer, Ph.D., executive vice president and chief science officer, will be making a presentation on the Company’s GEN-1 interleukin 12 (IL-12) immunotherapy program at the Cytokine-Based Cancer Immunotherapies Summit being held in Boston on November 30 to December 2, 2021. Dr. Anwer’s presentation, titled “A Non-Viral Gene Therapy Approach to IL-12 Delivery for The Treatment of Cancer,” will be delivered on December 2 at 8:10 a.m. Eastern time. The Company was invited to submit a poster presentation which aligns with Dr. Anwer’s oral presentation on the GEN-1 IL-12 program. The poster presentation will contain a subset of his presentation slides. Dr. Anwer will also be participating in two panel discussions.
In his presentation, Dr. Anwer will be discussing how local delivery of IL-12 without significant systemic toxicity is feasible with a non-viral gene therapy approach that involves administration of an IL-12 plasmid with a synthetic DNA delivery system (GEN-1). Dr. Anwer will also be discussing how weekly intraperitoneal administration of GEN-1 yields durable increases in IL-12 and IFN-, and why repeated weekly administration of GEN-1 in combination with standard chemotherapy remodels the tumor immune environment to favor immune stimulation over immune suppression.
“We are pleased that the Cytokine-Based Cancer Immunotherapies Summit is recognizing Celsion’s leadership for and potential efficacy of cytokines as an immunotherapy for the treatment of serious malignancies,” said Michael H. Tardugno, chairman, president and chief executive officer of Celsion. “Results from the Company’s Phase I Study of GEN-1 in advanced ovarian cancer is attracting the interest of leading researchers in the field of immunotherapy.”
Dr. Anwer will also participate in two panel discussions:
- On December 1 at 8:30 a.m. Eastern time titled, “What Do We Know & Where Do We Want to Go?”
- On December 2 at 11:30 a.m. Eastern time titled “Side Effects – Mitigating Against Hypotension + Fever With Immune-Stimulating Agents (NK Cell Engagers, PD-1s, Cytokines, T-Cell Engagers) = Cytokine Release Syndrome (CRS)?”
About GEN-1 Immunotherapy
GEN-1, designed using Celsion’s proprietary TheraPlas™ platform technology, is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that enables cell transfection followed by persistent, local secretion of the IL-12 protein. IL-12 is one of the most active cytokines for the induction of potent anticancer immunity acting through the induction of T-lymphocyte and natural killer (NK) cell proliferation and maturation. The company previously reported positive safety and encouraging Phase I results with GEN-1 given as monotherapy or a combination therapy in patients with advanced peritoneally metastasized primary or recurrent ovarian cancer, and recently completed a Phase Ib dose-escalation trial (OVATION 1 Study) of GEN-1 in combination with carboplatin and paclitaxel in patients with newly diagnosed ovarian cancer. GEN-1 in combination with neoadjuvant chemotherapy is the subject of the ongoing randomized Phase II OVATION 2 Study in subjects with advanced-stage ovarian cancer (Stage III/IV), with enrollment now exceeding 75% and full enrollment targeted by the first half of 2022.
About Celsion
Corporation
Celsion is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies, and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV-2. The Company’s product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. Celsion also has two feasibility-stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anticancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection. For more information on Celsion, visit
www.celsion.com
.
Celsion GmbH is Celsion’s wholly owned, special purpose subsidiary based in Zug, Switzerland. Celsion GmbH is responsible for supporting studies of ThermoDox
®
, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. For more information on Celsion GmbH, visit
www.celsiongmbh.com
.
Forward-looking Statements
Forward-looking
statements
in
this
news
release
are
made
pursuant
to
the
“safe
harbor”
provisions
of
the
Private
Securities
Litigation
Reform
Act
of 1995.
These
statements
are
based
upon
current
beliefs,
expectation,
and
assumptions
and
include
statements
regarding
the
platform
having
the
potential
to
provide
broad
protection
against
coronavirus
disease
2019
(COVID-19),
and
possible
future
mutations
of
SARS-CoV-2
or
other
coronaviruses.
These
statements
are
subject
to
a
number
of
risks
and
uncertainties,
many
of
which
are
difficult
to
predict,
including
the
ability
of
the
Company’s
platform
to
provide
broad
protection
against
COVID-19,
and
possible
future
mutations
of
SARS-CoV-2
or
other
coronaviruses,
the
issuance
of
a
patent
to
the
Company
for
use
of
its
technology
platform
for
treating
or
preventing
infection
with
the
SARS-CoV-2
virus
that
causes
COVID-19,
unforeseen
changes
in
the
course
of
research
and
development
activities
and
in
clinical
trials;
the
uncertainties
of
and
difficulties
in
analyzing
interim
clinical
data,
particularly
in
small
subgroups
that
are
not
statistically
significant;
FDA
and
regulatory
uncertainties
and
risks;
the
significant
expense,
time
and
risk
of
failure
of
conducting
clinical
trials;
the
need
for
Celsion
to
evaluate
its
future
development
plans;
possible acquisitions
or
licenses
of
other
technologies,
assets
or
businesses;
possible
actions
by
customers,
suppliers,
competitors
or
regulatory
authorities;
and
other
risks
detailed
from
time
to
time
in
the
Celsion’s
periodic
filings
with
the
Securities
and
Exchange
Commission.
Celsion
assumes
no
obligation to update
or supplement
forward-looking
statements that
become untrue because
of
subsequent events,
new
information
or
otherwise.
CONTACTS:
Celsion Corporation
Jeffrey W. Church
Executive Vice President and CFO
609-482-2455
[email protected]
LHA Investor Relations
Kim Sutton Golodetz 212-838-3777
[email protected]
# # #
